FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605293431> ?p ?o ?g. }

• W2605293431 abstract "4550 Background: Tasquinimod (T) is an oral quinoline-3-carboxamide derivative that binds S100A9 protein and has preclinical anti-angiogenic and anti-tumor activity. Between 12/07-6/09, 201 (134 T, 67 Placebo (P)) men with metastatic CRPC were randomized and received treatment once-daily at an initial dose of 0.25 mg/day escalated to 1.0 mg/day over 4 weeks. Placebo patients could cross over to T after 6 months or at disease progression. The primary endpoint of improved PCWG2 criteria-defined progression at 6 months was met (69 vs. 37% of patients (T/P) were progression free) with PFS of 7.6 vs. 3.3 months for pts on T vs. P 1 with acceptable toxicity. This abstract provides the first analysis on symptomatic progression, overall survival (OS) as well as a multivariate analysis for PFS and OS. Methods: Survival data were collected between June 2011 and January 2012 with a median time to censoring of 32 months. Survival data was also evaluated in an exploratory multivariate model of known prognostic factors in CRPC. Results: An imbalance of several baseline prognostic criteria favored placebo (e.g. baseline PSA of 29 vs. 19 (T/P)) (JCO 2011;20:4022). Time to symptomatic progression was longer in T treated patients (p=0.039, HR=0.42). Record of death (97 events) or survival >13 months was documented in 182 patients. Median time to death was 34.2 vs. 30.2 months (T/P). Median time to death in the PCWG2 bone-metastatic subgroup (N=92/44) was 34.2 vs. 25.6 months. A multivariate analysis of known prognostic factors including PSA, LDH, PSA kinetics, and hemoglobin demonstrated an adjusted HR for PFS of 0.54 (95% CI 0.37,0.81) and OS of 0.72 (95% CI 0.46,1.12) in the total population and 0.63 (95% CI 0.37,1.07, n=136) in the bone-metastatic group. Conclusions: OS observed after tasquinimod treatment is longer than previously reported in this patient population. The current exploratory data indicates that the prolongation in PFS observed with tasquinimod treatment may lead to a survival advantage in men with metastatic CRPC. A phase III placebo-controlled study (NCT01234311) is ongoing in men with bone-metastatic CRPC powered to detect an OS improvement." @default.
• W2605293431 created "2017-04-14" @default.
• W2605293431 creator A5001771354 @default.
• W2605293431 creator A5001783218 @default.
• W2605293431 creator A5002966804 @default.
• W2605293431 creator A5003107448 @default.
• W2605293431 creator A5013015133 @default.
• W2605293431 creator A5024348621 @default.
• W2605293431 creator A5024372930 @default.
• W2605293431 creator A5031666641 @default.
• W2605293431 creator A5035534825 @default.
• W2605293431 creator A5038489185 @default.
• W2605293431 creator A5042053744 @default.
• W2605293431 creator A5046445815 @default.
• W2605293431 creator A5047408345 @default.
• W2605293431 creator A5057884041 @default.
• W2605293431 creator A5061052886 @default.
• W2605293431 creator A5068787756 @default.
• W2605293431 creator A5083635474 @default.
• W2605293431 creator A5088131964 @default.
• W2605293431 date "2012-05-20" @default.
• W2605293431 modified "2023-09-26" @default.
• W2605293431 title "Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial." @default.
• W2605293431 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.4550" @default.
• W2605293431 hasPublicationYear "2012" @default.
• W2605293431 type Work @default.
• W2605293431 sameAs 2605293431 @default.
• W2605293431 citedByCount "5" @default.
• W2605293431 countsByYear W26052934312013 @default.
• W2605293431 countsByYear W26052934312014 @default.
• W2605293431 crossrefType "journal-article" @default.
• W2605293431 hasAuthorship W2605293431A5001771354 @default.
• W2605293431 hasAuthorship W2605293431A5001783218 @default.
• W2605293431 hasAuthorship W2605293431A5002966804 @default.
• W2605293431 hasAuthorship W2605293431A5003107448 @default.
• W2605293431 hasAuthorship W2605293431A5013015133 @default.
• W2605293431 hasAuthorship W2605293431A5024348621 @default.
• W2605293431 hasAuthorship W2605293431A5024372930 @default.
• W2605293431 hasAuthorship W2605293431A5031666641 @default.
• W2605293431 hasAuthorship W2605293431A5035534825 @default.
• W2605293431 hasAuthorship W2605293431A5038489185 @default.
• W2605293431 hasAuthorship W2605293431A5042053744 @default.
• W2605293431 hasAuthorship W2605293431A5046445815 @default.
• W2605293431 hasAuthorship W2605293431A5047408345 @default.
• W2605293431 hasAuthorship W2605293431A5057884041 @default.
• W2605293431 hasAuthorship W2605293431A5061052886 @default.
• W2605293431 hasAuthorship W2605293431A5068787756 @default.
• W2605293431 hasAuthorship W2605293431A5083635474 @default.
• W2605293431 hasAuthorship W2605293431A5088131964 @default.
• W2605293431 hasConcept C121608353 @default.
• W2605293431 hasConcept C126322002 @default.
• W2605293431 hasConcept C126894567 @default.
• W2605293431 hasConcept C142724271 @default.
• W2605293431 hasConcept C143998085 @default.
• W2605293431 hasConcept C168563851 @default.
• W2605293431 hasConcept C204787440 @default.
• W2605293431 hasConcept C27081682 @default.
• W2605293431 hasConcept C2780192828 @default.
• W2605293431 hasConcept C3019894029 @default.
• W2605293431 hasConcept C71924100 @default.
• W2605293431 hasConceptScore W2605293431C121608353 @default.
• W2605293431 hasConceptScore W2605293431C126322002 @default.
• W2605293431 hasConceptScore W2605293431C126894567 @default.
• W2605293431 hasConceptScore W2605293431C142724271 @default.
• W2605293431 hasConceptScore W2605293431C143998085 @default.
• W2605293431 hasConceptScore W2605293431C168563851 @default.
• W2605293431 hasConceptScore W2605293431C204787440 @default.
• W2605293431 hasConceptScore W2605293431C27081682 @default.
• W2605293431 hasConceptScore W2605293431C2780192828 @default.
• W2605293431 hasConceptScore W2605293431C3019894029 @default.
• W2605293431 hasConceptScore W2605293431C71924100 @default.
• W2605293431 hasLocation W26052934311 @default.
• W2605293431 hasOpenAccess W2605293431 @default.
• W2605293431 hasPrimaryLocation W26052934311 @default.
• W2605293431 hasRelatedWork W2103959341 @default.
• W2605293431 hasRelatedWork W2110534364 @default.
• W2605293431 hasRelatedWork W2123526148 @default.
• W2605293431 hasRelatedWork W2130088545 @default.
• W2605293431 hasRelatedWork W2148643283 @default.
• W2605293431 hasRelatedWork W2158011521 @default.
• W2605293431 hasRelatedWork W2165088640 @default.
• W2605293431 isParatext "false" @default.
• W2605293431 isRetracted "false" @default.
• W2605293431 magId "2605293431" @default.
• W2605293431 workType "article" @default.